Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Non-Current Debt (2016 - 2021)

Historic Non-Current Debt for BioRestorative Therapies (BRTX) over the last 11 years, with Q4 2021 value amounting to $250000.0.

  • BioRestorative Therapies' Non-Current Debt fell 9414.55% to $250000.0 in Q4 2021 from the same period last year, while for Dec 2021 it was $250000.0, marking a year-over-year decrease of 9414.55%. This contributed to the annual value of $250000.0 for FY2021, which is 9414.55% down from last year.
  • Latest data reveals that BioRestorative Therapies reported Non-Current Debt of $250000.0 as of Q4 2021, which was down 9414.55% from $5.8 million recorded in Q3 2021.
  • In the past 5 years, BioRestorative Therapies' Non-Current Debt registered a high of $5.8 million during Q3 2021, and its lowest value of $61686.0 during Q3 2017.
  • For the 5-year period, BioRestorative Therapies' Non-Current Debt averaged around $1.6 million, with its median value being $225400.0 (2019).
  • In the last 5 years, BioRestorative Therapies' Non-Current Debt surged by 183060.18% in 2018 and then plummeted by 9414.55% in 2021.
  • BioRestorative Therapies' Non-Current Debt (Quarter) stood at $194282.0 in 2017, then soared by 169.66% to $523894.0 in 2018, then crashed by 70.0% to $157143.0 in 2019, then skyrocketed by 2617.42% to $4.3 million in 2020, then crashed by 94.15% to $250000.0 in 2021.
  • Its last three reported values are $250000.0 in Q4 2021, $5.8 million for Q3 2021, and $4.8 million during Q2 2021.